Dr Cornelis van Tilburg speaks to ecancer about the clinical outcome and benefit for molecular subgroups seen in the paediatric precision oncology study INFORM that was presented at the 2020 ASCO Virtual Meeting.
He explains that INFORM is a non-interventional registry study that provided comprehensive molecular diagnostics and also clinical follow up allowing insight into treatments that benefit in certain alterations.
Dr van Tilburg reports that the study found that patients labelled with 'high level priority' alterations greatly benefited when treated with targeted drugs.
Read more about the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.